Lactiga’s secretory IgA replacement therapy for compromised immune function receives NIAID funding
Feb. 4, 2025
Lactiga Inc. has been awarded a multiyear grant by the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate the advancement of the company’s lead asset, LCTG-001.
